Dr. Frances Shepherd CV - (NCRI) is

23. Jang RW, LeMaitre A, Ding K, Winton TL, Bezjak A, Seymour L, Shepherd FA, Leighl
N. A Q-TwiST analysis of adjuvant chemotherapy in non-small cell lung cancer
(NSCLC) in the NCIC CTG JBR.10 trial. Presented at ASCO June 2008.
24. Tsao MS, Zhu C, Ding K, Strumpf D, PintileM, Meyerson M, Seymour L, Jurisica I,
Shepherd FA. A 15-gene expression signature prognostic for survival and predictive for
adjuvant chemotherapy benefit in JBR.10 patients. Presented at ASCO June 2008.
25. Brade AM, Bezjak A, MacRae R, Laurie SA, PondGR, Wang L, Dick C, Afinec A, Iscoe
N, Shepherd FA. A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation
(RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC). Presented at
ASCO June 2008.
26. Wheatley-Price P, LeMaitre A, Ding K, Leighl NB, Hirsch V, Seymour L, Shepherd FA.
The influence of sex on efficacy, toxicity and delivery of treatment in National Cancer
Institute of Canada Clinical Trials Group (NCIC CTG) non-small cell lung cancer
(NSCLC) chemotherapy trials. Presented at ASCO June 2008.
27. LeMaitre A, Ding K, Shepherd FA, Leighl NB, Arnold A, Seymour L. Anticoagulation
and bleeding: A pooled analysis of lung cancer trials of the National Cancer Institute of
Canada Clinical Trials Group. Presented at ASCO June 2008.
28. Horgan AM, Shepherd FA, Bradbury PA, Ng R, Leighl NB. Preliminary costconsequence
analysis in INTEREST trial, a randomized trial of docetaxel versus
gefitinibas 2 nd line therapy in advanced non-small cell lung cancer. Presented at ASCO
June 2008.
29. Vincent MD, Butts C, Seymour L, Ding K, Graham B, Twumasi-Ankrah P, Gandara D,
Schiller J, Green M, Shepherd FA. Updated survival analysis of JBR.10: A randomized
phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB
and II non-small cell lung cancer (NSCLC). Presented at ACO 2009.
30. Richardson F, Richardson K, Sennello G, Young D, Orlov S, Papal-Szekely Z, Keshavjee
S, Kim J, Cerfolio R, Shepherd FA. Biomarker analysis from completely resected
NSCLC patients enrolled in an adjuvant erlotinib clinical trial (RADIANT). Presented at
ASCO 2009.
31. Goodwin RA, Seymour L, Ding K, Gouthier I, Le Maitre A, Frymire E. Arnold A,
Shepherd FA, Goss GD. Hypertension (HTN) in National Cancer Institute of Canada
Clincial Trials Group study BR.24: A randomized, double-blinded phase II trial of
carboplatin (C) and paclitaxel (P) with either daily oral cediranib (CED), an inhibitor of
vascular endothelial growth factor receptors, or placebo, in patients with advanced nonsmall
cell lung cancer. Presented at ASCO 2009.
32. Shepherd FA, Douillard J, Fukuoka M, Saijo N, Kim s, Cufer T, Sellers MV, Armour
AA, Kim ES. Comparison of gefitinib and docetaxel in patienst with pretreated advanced
non-small cell lung cancer (NSCLC): Meta-analysis from four clinical trials. Presented at
ASCO 2009.
33. Bradbury PA, Twumasi-Ankrah P, Ding K, Leighl NB, Goss GD, Laurie S, Shepherd
FA, Seymour L. The impact of brain metastases on overall survival (OS) in National
Cancer Institute of Canada Clinical Trials Grooup(NCIC CTG) clinical trials (CT) in
advanced non-small cell lung cancer (NSCLC). Presented at ASCO 2009.
34. Bahleda R, Soria J, Harbison C, Park J, Felip E, Hanna N, Laurie SA, Armand J,
Shepherd FA. Tumor regression and pharmacodynamic (PD) biomarker validation in
non-small cell lung cancer (NSCLC) patients treated with the ErbB/VEGFR inhibitor
BMS-690514. Presented at ASCO 2009.
35. Goss GD, Addison C, Shepherd FA, Seymour L. TGF-cx and amphiregulin levels in
non-small cell lung cancer (NSCLC) patients (pts) treated with erlotinib/placebo in
19